Skip to main content
Premium Trial:

Request an Annual Quote

Keep Placing Bets on the Table and You're Bound to Win

Google has invested in Navigenics, hoping to broaden its reach to include genetic information, say this Business Week article. As the media sees it, Navigenics is hoping to pull away from 23andMe (which Google also invested in). "23andMe has taken the approach of providing you a fun, social, and ancestral look at your DNA," says Amy DuRoss, head of policy and business affairs for Navigenics, whereas her company "has taken the view that science, clinical utility, and the ability to do something about your health is of paramount importance," she adds.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.